ROCKVILLE, Md., April 19, 2013 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused
on the prevention and treatment of serious infectious diseases,
reiterated that the Exclusive Channel Collaboration Agreement dated
August 6, 2012 between the Company
and Intrexon Corporation (Intrexon) remains in effect, as stated
earlier today. This Exclusive Channel Collaboration Agreement
governs a "channel collaboration" arrangement for the use of
Intrexon's technology relating to the identification, design and
production of human antibodies and DNA vectors for the development
and commercialization of a series of monoclonal antibody therapies
for the treatment of certain serious infectious diseases.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of biologics for the prevention
and treatment of serious infectious diseases. The Company is
developing an oral enzyme for the prevention of C. difficile
infections, and a series of monoclonal antibody therapies for the
treatment of Pertussis and Acinetobacter infections. In
addition, the Company is developing a drug candidate for the
treatment of relapsing-remitting multiple sclerosis and cognitive
dysfunction in multiple sclerosis. For more information, please
visit Synthetic Biologics' website at
www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.